GlassScriptPhysician profile
Carol Lynn Cherry
NPI 1366923096
$1,369.99
in general payments reported to CMS, 2019-2025
15 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $338 · 2022: $307 · 2023: $71.58 · 2024: $287 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $502.68 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $205.05 | 2021-2025 | Xtampza, Belbuca |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.99 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Astellas Pharma US INC | $121.44 | 2024 | Veozah |
| Biodelivery Sciences International, INC. | $56.40 | 2021 | |
| Viiv Healthcare Company | $35.45 | 2022 | |
| Protega Pharmaceutials INC | $31.80 | 2024 | Roxybond |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.13 | 2021 | |
| Forte Bio-Pharma LLC | $23.62 | 2024 | Prolate, Nalocet |
| Karyopharm Therapeutics INC. | $19.68 | 2024 | Xpovio |
| Antares Pharma, INC. | $19.45 | 2021 | |
| Scilex Pharmaceuticals INC. | $17.27 | 2023 | Ztlido |
| Boston Scientific Corporation | $14.16 | 2022 | |
| Horizon Therapeutics Plc | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.